相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Des-gamma-Carboxyprothrombin May Be a Promising Biomarker to Determine the Therapeutic Efficacy of Sorafenib for Hepatocellular Carcinoma
Kazuomi Ueshima et al.
DIGESTIVE DISEASES (2011)
Management of Hepatocellular Carcinoma in Japan: Consensus-Based Clinical Practice Guidelines Proposed by the Japan Society of Hepatology (JSH) 2010 Updated Version
Masatoshi Kudo et al.
DIGESTIVE DISEASES (2011)
The 2008 Okuda lecture: Management of hepatocellular carcinoma: From surveillance to molecular targeted therapy
Masatoshi Kudo
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2010)
The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma
Ledu Zhou et al.
MEDICAL ONCOLOGY (2010)
Positioning of a Molecular-Targeted Agent, Sorafenib, in the Treatment Algorithm for Hepatocellular Carcinoma and Implication of Many Complete Remission Cases in Japan
Masatoshi Kudo et al.
ONCOLOGY (2010)
Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis
S. J. Schoenleber et al.
BRITISH JOURNAL OF CANCER (2009)
A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer
Ramesh K. Ramanathan et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2009)
A Multi-Institutional Phase II Study of the Efficacy and Tolerability of Lapatinib in Patients with Advanced Hepatocellular Carcinomas
Tanios Bekaii-Saab et al.
CLINICAL CANCER RESEARCH (2009)
Pathogenesis of hepatocellular carcinoma and molecular therapies
Beatriz Minguez et al.
CURRENT OPINION IN GASTROENTEROLOGY (2009)
mTOR inhibitors for hepatocellular cancer: a forward-moving target
Gerhard Treiber
EXPERT REVIEW OF ANTICANCER THERAPY (2009)
Involvement of PI3K/PTEN/AKT/mTOR pathway in invasion and metastasis in hepatocellular carcinoma: Association with MMP-9
Jing-song Chen et al.
HEPATOLOGY RESEARCH (2009)
A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer
J. Randolph Hecht et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase II Trial of the Combination of Bevacizumab and Erlotinib in Patients Who Have Advanced Hepatocellular Carcinoma
Melanie B. Thomas et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Efficacy, Safety, and Potential Biomarkers of Sunitinib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study
Andrew X. Zhu et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Angiogenesis in liver disease
Mercedes Fernandez et al.
JOURNAL OF HEPATOLOGY (2009)
Sunitinib and the benefits of a negative study
Alejandro Forner et al.
LANCET ONCOLOGY (2009)
Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study
Sandrine Faivre et al.
LANCET ONCOLOGY (2009)
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
Ann-Lii Cheng et al.
LANCET ONCOLOGY (2009)
Targeted therapy for hepatocellular carcinoma
Hans Christian Spangenberg et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2009)
Differential Roles of Insulin-like Growth Factor Receptor- and Insulin Receptor-mediated Signaling in the Phenotypes of Hepatocellular Carcinoma Cells
Ya-Wen Chen et al.
NEOPLASIA (2009)
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
Jeffrey A. Engelman
NATURE REVIEWS CANCER (2009)
Epidermal growth factor receptor expression and gene copy number in conventional hepatocellular carcinoma
Anne F. Buckley et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2008)
Pivotal Role of mTOR Signaling in Hepatocellular Carcinoma
Augusto Villanueva et al.
GASTROENTEROLOGY (2008)
Molecular targeted therapies in hepatocellular carcinoma
Josep M. Llovet et al.
HEPATOLOGY (2008)
Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity
Nilofer S. Azad et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma
Abby B. Siegel et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling
Scott M. Wilhelm et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Drug development of MET inhibitors: targeting oncogene addiction and expedience
Paolo M. Comoglio et al.
NATURE REVIEWS DRUG DISCOVERY (2008)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Drug therapy: EGFR antagonists in cancer treatment
Fortunato Ciardiello et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Hepatocellular Carcinoma 2009 and Beyond: from the Surveillance to Molecular Targeted Therapy
Masatoshi Kudo
ONCOLOGY (2008)
Growth factor receptors and related signalling pathways as targets for novel treatment strategies of hepatocellular cancer
Michael Hoepfner et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2008)
VEGF-A splicing: the key to anti-angiogenic therapeutics?
Steven J. Harper et al.
NATURE REVIEWS CANCER (2008)
Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma
Melanie B. Thomas et al.
CANCER (2007)
Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma
Andrew X. Zhu et al.
CANCER (2007)
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
P. J. Roberts et al.
ONCOGENE (2007)
Genomics and signaling pathways in hepatocellular carcinoma
Augusto Villanueva et al.
SEMINARS IN LIVER DISEASE (2007)
Phase II study of sorafenib in patients with advanced hepatocellular carcinoma
Ghassan K. Abou-Alfa et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: Five-year follow-up of Southwest Oncology Group protocol S9911
Oliver W. Press et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Ubiquitous activation of Ras and Jak/Stat pathways in human HCC
DF Calvisi et al.
GASTROENTEROLOGY (2006)
Genetics of hepatocellular tumors
P. Laurent-Puig et al.
ONCOGENE (2006)
Hepatocellular carcinoma pathogenesis: from genes to environment
Paraskevi A. Farazi et al.
NATURE REVIEWS CANCER (2006)
Raf: A strategic target for therapeutic development against cancer
M Beeram et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase II study of erlotinib (OSI-774) in patients with advanced hepatocellular cancer
PA Philip et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas
HA Burris et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Platelet-derived growth factor C induces liver fibrosis, steatosis, and hepatocellular carcinoma
JS Campbell et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition
JF Ohren et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2004)
Over-expression of c-raf-1 proto-oncogene in liver cirrhosis and hepatocellular carcinoma
YH Hwang et al.
HEPATOLOGY RESEARCH (2004)
Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: Its role in tumor progression and apoptosis
H Huynh et al.
BMC GASTROENTEROLOGY (2003)
Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma
A Tannapfel et al.
GUT (2003)
分享论文
